In millions of USD; shares in millions, except per-share amounts
Q2 FY2026
As of Jun 30, 2026
Q1 FY2026
As of Mar 31, 2026
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
Assets:
Cash and cash equivalents
Investments
Accounts receivable, net
Inventories
Assets held for sale
Other current assets
Total current assets
Long-term investments
Property and equipment, net
Operating lease right-of-use assets
Goodwill
Intangible assets, net
Separate accounts assets
Other assets
Total assets
Liabilities:
Accounts payable
Pharmacy claims and discounts payable
Health care costs payable
Policyholders’ funds
Accrued expenses and other current liabilities
Other insurance liabilities
Current portion of operating lease liabilities
Short-term debt
Current portion of long-term debt
Liabilities held for sale
Total current liabilities
Long-term operating lease liabilities
Long-term debt
Deferred income taxes
Separate accounts liabilities
Other long-term insurance liabilities
Other long-term liabilities
Total liabilities
Shareholders’ equity:
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding
Common stock, par value $0.01: 3,200 shares authorized; 1,795 shares issued and 1,278 shares outstanding as of June 30, 2026 and 1,787 shares issued and 1,271 shares outstanding as of December 31, 2025 and capital surplus
Treasury stock, at cost: 480 shares at March 31, 2023 and 458 shares at December 31, 2022
Treasury stock, at cost: 517 and 516 shares as of June 30, 2026 and December 31, 2025
